Haoyunbang Closes a New Round of Financing

(VCBeat) Feb. 4, 2021 -- Haoyunbang, a company building fertility clinics for infertility, closed a new round of financing led by Green Pine Capital Partners. The fresh round of funding will be used to improve Haoyunbang’s reproductive specialty services, build subdivided disease management systems, and introduce and develop professional talent teams.

This is another round of financing for Haoyunbang after receiving the investment from Qingke Asset Management Center in June 2020. Prior to this, the company had raised five rounds of financing from Gene Capital and Boxing Capital, etc.

Since its establishment in 2014, Haokubang has been deeply engaged in the field of reproductive biology. Over the past six years, Haokubang has explored and tried a variety of business models and commercial paths, giving the whole team a deeper understanding of the reproductive industry. Taking advantage of its own online platform, Haokubang insists on taking outpatient service as its core, and gradually formed the closed loop of online platform and online outpatient service. 

As the offline physical brand of Haoyundang, Huasheng Medical adheres to the medical concept of MDT (the multidisciplinary team approach) and the service concept of "combination of management and treatment". Huasheng Medical is a top medical group composed of 70 experts in different sectors of the reproductive field. At present, Huasheng Medical has built 7 medical institutions in Beijing, Guangzhou and other places, cooperated with 20 first-class hospitals at grade 3, and built an IVF center in Thailand, which has completely set a complete loop of reproductive services.

The advantages of HaoyunBang's online platform are also outstanding. It is the largest platform in the field of infertility in China, with more than 11 million users and more than 10,000 specialists in the field of reproduction.

In addition, the HuaSheng Cloud SaaS system independently developed by HaoyunBang ensures the standardization and reproducibility of the medical services provided in its outpatient clinics, including the configuration and integration of the underlying supply chain of the clinic chains.

Founded in 1997 by Mr. Li Wei and Mr. Luo Fei, GPCP is headquartered in Shenzhen and has offices in Beijing, Shanghai and Guangzhou.  GPCP has rich practical experience in venture investment, specializing in innovative technologies and focusing on platform building. 

GPCP has been consistently focusing on Strategic Emerging Industries including Artificial Intelligence, Smart Manufacturing, Precision Medicine, New Materials and New Energy.